Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19105611 | 0.93 | TGFBR1 (0.35) | NR3C2TGFBR1MAP3K12TRPV1 | |
| SCHEMBL19954611 | 0.92 | MPO (0.35) | NR3C2SMYD3TGFBR1MAP3K12 | |
| SCHEMBL19954553 | 0.87 | NR3C2 (0.40) | NR3C2TGFBR1MAP3K12TRPV1 | |
| SCHEMBL19954663 | 0.87 | NR3C2 (0.38) | NR3C2TGFBR1MAP3K12TRPV1 | |
| SCHEMBL19954523 | 0.86 | TGFBR1 (0.35) | NR3C2TGFBR1MAP3K12TRPV1 | |
| SCHEMBL21024127 | 0.85 | NR3C2 (0.40) | NR3C2TGFBR1MAP3K12TRPV1 | |
| SCHEMBL19954537 | 0.83 | PLAT (0.42) | NR3C2TGFBR1MAP3K12 | |
| SCHEMBL21023784 | 0.83 | NR3C2 (0.36) | NR3C2TGFBR1MAP3K12TRPV1 | |
| SCHEMBL19954606 | 0.83 | TGFBR1 (0.41) | NR3C2TGFBR1MAP3K12 | |
| SCHEMBL19954525 | 0.83 | SMN1; SMN2 (0.37) | NR3C2TGFBR1MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3080087-B1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | ATP5F1A, ATP5ME, ATP5F1D | NR3C2 4324/4885SMYD3 3526/4885TGFBR1 4644/4885 |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | NR3C2 4324/4885SMYD3 3526/4885TGFBR1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.